Otsuka (OTCMKTS:OTSKY) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) saw unusually-high trading volume on Wednesday . 35,632 shares were traded during mid-day trading, a decline of 12% from the previous session’s volume of 40,304 shares.The stock last traded at $33.69 and had previously closed at $33.88.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Otsuka from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Otsuka Stock Performance

The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17. The stock’s 50-day simple moving average is $34.54 and its two-hundred day simple moving average is $33.05. The stock has a market cap of $36.29 billion and a price-to-earnings ratio of 14.25.

Otsuka (OTCMKTS:OTSKY) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.16. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.The business had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. Analysts forecast that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 earnings per share for the current year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.